

Q2: Quarterly Industry Update

AS OF June 30, 2021



Blood Diagnostics

INDUSTRY SUMMARY

Cogent Valuation identified Blood Diagnostics publicly traded companies IPOs, and recent M&A transactions within the Blood Diagnostics industry, which provides a basis for market and transaction pricing that can be used by your firm in estimating market sentiment and its impact on your firm's value. Over the last year since June 30, 2020, the median 52-week share price return of the Blood Diagnostics industry was 29.8%. Between June 30, 2020 and June 30, 2021, the median EV/EBITDA multiple decreased from 17.3 to 16.2. However, the median price-to-earnings multiple increased from 28.5 to 29.7 over the same period. The median revenue growth and EBITDA margins for the industry for the quarter were 2.0% and 4.0%, respectively.

Public Company Key Statistics

Median 52-Week
Return

29.8%

Median 3-Year CAGR
Return

14.9%

Median EV/Revenue
Multiple

6.3x

Median EV/EBITDA
Multiple

16.2x

Median Price/Earnings
Multiple

29.7x

Median EV/Gross CF
Multiple

25.7x

Comparable Public Company Market Price Returns as of June 30, 2021


| | 2021 | 3 Month | 1 Year | 2 Year | 3 Year | 2020 | 2019 | 2018 |
|-------------------------------------|--------|---------|--------|--------|--------|--------|--------|--------|
| Abaxis, Inc. | 67.6% | 67.6% | 45.6% | 24.7% | 6.2% | -22.8% | -2.0% | 42.0% |
| DexCom, Inc. | 109.7% | 109.7% | -20.0% | -57.8% | -0.2% | -3.9% | -36.1% | 10.8% |
| Escalon Medical Corp. | 65.5% | 65.5% | -12.5% | 4.5% | -77.6% | 99.9% | -80.2% | -55.7% |
| Insulet Corporation | 9.5% | 9.5% | 200.0% | -38.7% | -38.8% | 83.1% | -82.8% | -17.3% |
| Masimo Corporation | 25.3% | 25.3% | 101.2% | 61.7% | -50.4% | 25.8% | -56.2% | 16.1% |
| Quest Diagnostics Incorporated | -2.0% | -2.0% | -5.7% | 45.0% | -4.9% | -6.2% | 42.3% | -32.9% |
| Median of Industry Public Companies | 24.2% | 24.2% | 2.1% | 18.5% | -4.9% | 7.2% | -17.9% | -3.3% |


Multiple year periods are calculated as the average annual return.


■ Highest Return
 ■ Lowest Return
 ■ Median Return

Public Company Median Multiples by Quarter

| | 6/30/21 | 3/31/21 | 12/31/20 | 9/30/20 | 6/30/20 | 3/31/20 | 12/31/19 | 9/30/19 |
|-------------------------------------|---------|---------|----------|---------|---------|---------|----------|---------|
| EV/Revenues Multiple | 4.7x | 5.6x | 5.1x | 5.1x | 5.5x | 6.0x | 6.3x | 4.4x |
| EV/EBITDA Multiple | 11.6x | 11.9x | 11.4x | 11.0x | 16.1x | 18.1x | 19.0x | 14.8x |
| Price/Earnings Multiple | 17.0x | 18.4x | 17.4x | 17.2x | 15.9x | 17.9x | 17.3x | 15.4x |
| EV/Gross Cash Flows Multiple | 16.9x | 18.3x | 17.7x | 17.7x | 15.2x | 16.9x | 16.5x | 14.7x |

 Highest Multiple

 Lowest Multiple

 Median Multiple

Industry Initial Public Offerings—Blood Diagnostics

(dollars in millions, except share prices)

| Offer Date | Company Name | Offer Price | Shares Offered | Amount Raised | Total Assets | Debt | LTM Revenues | LTM EBITDA | LTM Net Income | LTM Cash Flows |
|---------------------------|---|-------------|----------------|---------------|---------------|--------------|---------------|--------------|----------------|----------------|
| 6/9/21 | HK Biomedicine Co.,Ltd. | \$3.09 | 4.7 | \$3.2 | \$0.6 | \$0.3 | \$27.1 | \$150 | (\$0.2) | (\$0.2) |
| 5/13/21 | Hemcheck Sweden AB (publ) | \$0.67 | 1.5 | \$10.4 | \$8.6 | \$0.9 | \$0.2 | N/A | (\$1.9) | (\$1.9) |
| 12/17/20 | PCL, Inc. | \$6.94 | 2.9 | \$17.1 | \$2.7 | \$3.2 | \$0.5 | (\$7.7) | (\$5.7) | (\$4.5) |
| 11/29/20 | ExpreS2ion Biotech Holding AB (publ) | \$0.70 | 2.0 | \$12.0 | \$3.3 | \$0.0 | N/A | (\$23.6) | (\$4.2) | (\$3.9) |
| 7/9/19 | Cellnovo Group SA | \$11.73 | 5.2 | \$57.2 | \$25.8 | \$4.6 | \$0.2 | (\$8.3) | (\$23.0) | (\$20.8) |
| 4/30/14 | T2 Biosystems, Inc. | \$11.00 | 5.0 | \$60.0 | \$56.3 | \$9.7 | \$0.1 | \$127.1 | (\$30.2) | (\$24.6) |
| 4/24/14 | Globus Medical, Inc. | \$8.00 | 0.9 | \$8.5 | \$3.5 | \$27.2 | \$27.1 | (\$4.8) | (\$2.3) | (\$0.2) |
| 10/18/11 | Globus Medical, Inc. | \$13.00 | 5.0 | \$40.0 | \$26.4 | \$15.0 | \$0.8 | (\$14.1) | (\$6.6) | (\$5.0) |
| 2/3/11 | ZELTIQ Aesthetics, Inc. | \$7.00 | 1.9 | \$19.0 | \$1.1 | \$5.9 | \$227.4 | \$12.4 | (\$9.7) | (\$7.6) |
| 2/2/11 | BG Medicine, Inc. | \$7.00 | 5.0 | \$35.0 | \$6.0 | \$4.5 | \$1.0 | (\$15.4) | (\$18.1) | (\$14.9) |
| Median of all IPOs | | nm | nm | \$19.0 | \$13.4 | \$4.5 | \$40.7 | \$3.0 | (\$5.7) | (\$4.5) |

Size of Recent Merger and Acquisition Transactions for a Majority Stake (dollars in millions)

| Transaction Date | Target | Acquirer | Transaction Size | % Bought | LTM Revenues | EV/ Revenues |
|------------------|------------------------------|-----------------------------|------------------|----------|--------------|--------------|
| 6/11/21 | Exosome Diagnostics, Inc. | Bio-Techne Corporation | \$575.0 | 100% | N/A | 7.2x |
| 5/30/21 | Abaxis, Inc. | Zoetis Inc. | \$1,994.6 | 100% | \$244.7 | 4.4x |
| 12/20/20 | ViroGates A/S | N/A | \$11.7 | 78% | \$0.3 | 2.6x |
| 11/4/19 | Cepheid | Danaher Corporation | \$4,402.2 | 100% | \$564.2 | 3.7x |
| 6/29/19 | Nanosphere, Inc. | Luminex Corporation | \$114.7 | 100% | \$23.0 | 4.1x |
| 9/29/17 | Health Diagnostic Laboratory | CareDx, Inc | \$38.4 | 100% | \$16.4 | N/A |
| 6/11/17 | Biosensors International | Hony Capital (Beijing) | \$1,466.6 | 100% | \$359.8 | N/A |
| 11/20/16 | LipoScience, Inc. | Laboratory Corp. of America | \$101.2 | 100% | \$45.5 | 1.3x |
| 10/31/16 | Cell Marque Corporation | Sigma-Aldrich Corporation | \$170.0 | 100% | N/A | N/A |
| 11/4/15 | Flowsense Medical | Baxter International | \$50.0 | 100% | \$0.1 | N/A |
| 11/20/14 | Cepheid | Baxter International | \$101.2 | 100% | \$1,670.7 | 2.4x |
| 8/1/18 | Cell Marque Corporation | Inverness Medical | \$170.0 | 100% | N/A | N/A |
| 7/31/18 | Flowsense Medical | ERBA Diagnostics | \$4.5 | 100% | \$13.0 | 0.5x |
| 6/20/18 | Gambro AB | Hologic | \$4,204.1 | 100% | \$586.6 | 6.6x |
| 2/6/13 | SunTech Medical Group | Halma | \$57.0 | 100% | \$23.0 | 2.3x |
| 10/3/12 | Navilyst Medical | AngioDynamics | \$374.5 | 100% | \$148.6 | 2.5x |

 USA
  International



(Continued on next page)

Size of Recent Merger and Acquisition Transactions for a Majority Stake (dollars in millions)

Continued from previous page

| Transaction Date | Target | Acquirer | Transaction Size | % Bought | LTM Revenues | EV/ Revenues |
|--|------------------------------------|---------------------------|------------------|----------|--------------|--------------|
| 4/2/12 | Accutome | Halma | \$25.0 | 100% | \$20.2 | 1.2x |
| 1/3/12 | Verum Diagnostica | Roche Holding | \$13.3 | 100% | N/A | N/A |
| 11/23/11 | Shanghai Yuanqi | SHMY Healthdigit Biochips | \$54.0 | 70% | \$0.1 | N/A |
| 11/8/11 | Axis-Shield | Alere | \$396.1 | 100% | \$164.7 | 2.3x |
| 9/2/11 | Life Enhancement Technology | VasoHealthcare | \$3.3 | 100% | N/A | N/A |
| 8/23/11 | Phadia | Thermo Fisher Scientific | \$3,512.8 | 100% | \$523.4 | 6.7x |
| 6/29/11 | Beckman Coulter | Danaher | \$7,392.9 | 100% | \$3,663.4 | 1.9x |
| Median of the 23 M&A Transaction Targets | | | \$101.2 | 100% | \$45.5 | 2.5x |

Recent Merger and Acquisition Transactions for a Majority Stake (dollars in millions) as June 30, 2021



Definitions of Financial Terms Used in this Quarterly Industry Update:

Enterprise Value (EV): Market Value of Equity + Market Value of Debt —Cash

Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA): Referred to as operating profit or operating earnings.

Gross Cash Flows: Net Income + Depreciation and Amortization Expense

Latest Twelve Months (LTM): Financial information is as of the latest twelve months through the date of this Quarterly Industry Update.

Disclosures and Limitations: This research report is for informational and discussion purposes only. Information presented herein is not investment advice of any kind to any person and does not constitute a recommendation as to the purchase or sale of any interests or as to any other course of action. General, financial, and statistical information concerning the details of this report and related industry are from sources Cogent Valuation believes to be reliable. Cogent Valuation has accurately reflected such information in this research report; however, Cogent Valuation makes no representation as to the sources' accuracy or completeness and has accepted this information without further verification. Neither all nor any part of the content of this report may be conveyed to the public through advertising, public relations, news, sales, mail, direct transmittal, or other media without the prior written consent of Cogent Valuation. Cogent Valuation's research is as of the date reported herein. Cogent Valuation has no affiliation with any of the companies comprising the industry used as a basis for research in this report, nor does Cogent Valuation hold any investments in the companies listed herein. The content of this report may be used, in part, as a basis for any work that Cogent Valuation performs for you in the future at the sole discretion of Cogent Valuation. THIS REPORT IS NOT TO BE USED OR CONSIDERED UNDER ANY CIRCUMSTANCE BY ANYONE AS INVESTMENT ADVICE.

COGENT VALUATION is a nationally recognized full service business valuation firm that has provided independent valuation and financial advisory opinions in thousands of situations since 1991. These assignments include the valuation of companies and pass-through entities, their securities, and their intangible assets ranging in size from small, closely-held businesses and start-ups, to corporations with market values over a billion dollars, covering almost every industry and all types of transactions. With the collective backgrounds of our managing directors and professional staff, Cogent Valuation brings substantial large deal experience to bear on our middle market transaction opinions. Cogent Valuation utilizes proprietary research, intensive due diligence, and the experience and insights of its professionals to produce thoughtful, well-documented opinions that have consistently withstood the scrutiny of clients and their advisors, investors, regulators, and courts.

This industry research is provided at no charge to Cogent Valuation's clients. Research or detailed information not covered in this report can be obtained for a fee. **Contact Steven Kam at 415-392-0888** for additional information or questions in connection with this research report.